Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial.

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiat Oncol Biol Phys. 1993 Jul 15; 26(4):721-9.

View in: PubMed

subject areas

Adenocarcinoma
Anemia
Breast Neoplasms
Combined Modality Therapy
Erythropoietin
Female
Humans
Injections, Subcutaneous
Lung Neoplasms
Male
Middle Aged
Prospective Studies
Prostatic Neoplasms
Recombinant Proteins

authors with profiles

Azhar M. Awan
Susan Rubin
Howard Halpern